Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study

出版年份 2019 全文链接

标题

作者

关键词

atopic dermatitis, biologic therapy, dupilumab, IL-4, IL-13, long-term, open label, monoclonal antibody, efficacy, quality of life, safety

出版物

Volume -, Issue -, Pages -

出版商

Elsevier BV

发表日期

2019-07-31

DOI

10.1016/j.jaad.2019.07.074

联系作者

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started